Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
Completed · Phase 1
Conditions studied: Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma
In brief
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with TGR-1202, with or without ibrutinib or bendamustine, in patients with advanced hematologic malignancies
Key facts
- Study ID
- NCT02006485
- Run by
- TG Therapeutics, Inc.
- People needed
- 160
- Starts
- 2013-12-13
- Expected to finish
- 2019-10-01
- Last updated by the study team
- 2019-11-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Confirmed B-cell non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and other B-cell lymphoproliferative disorders as approved by the Medical Monitor or Study Chair
- Refractory to or relapsed after at least 1 prior treatment regimen
- Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
You may not qualify if…
- Any major surgery, chemotherapy or immunotherapy within the last 21 days
- Known hepatitis B virus, hepatitis C virus or HIV infection
- Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months
- Primary central nervous system lymphoma or known intracranial involvement
Where it is running
- TG Therapeutics Investigational Trial Site — Huntsville, Alabama, United States
- TG Therapeutics Investigational Trial Site — Jonesboro, Arkansas, United States
- TG Therapeutics Investigational Trial Site — Duarte, California, United States
- TG Therapeutics Investigational Trial Site — Atlanta, Georgia, United States
- TG Therapeutics Investigational Trial Site — Omaha, Nebraska, United States
- MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.